BioMed Nexus Daily Updates
Your essential biotech, medtech, and pharma recap — no noise, just what matters.
📌TL;DR
Merck and Moderna's Phase 3 INTerpath-001 trial of intismeran autogene plus Keytruda met its primary endpoint of recurrence free survival and its key secondary endpoint of distant metastasis free survival in 1,137 patients with resected stage IIB to IV melanoma at a prespecified interim analysis; no effect sizes were disclosed, and data will be presented at an upcoming medical meeting.
Amylyx announced a $350.0 million proposed public offering of common stock, with a 30 day underwriters option for up to $52.5 million more, one day after its avexitide Phase 3 win; proceeds fund pre commercial work including manufacturing capacity.
President Trump formally announced the nomination of Dr. Heidi Overton as FDA commissioner on Wednesday via Truth Social; Senate confirmation is required and no hearing date has been set.
The D.C. Circuit rejected Teva's core challenges to Medicare drug price negotiation but revived its claim against CMS's bona fide marketing standard, remanding that question to the district court.
Tolerance Bio licensed NeoImmuneTech's efineptakin alfa, a long acting IL-7 fusion protein, for equity plus up to $260 million in milestones plus royalties, with Phase 2 plans in thymic function enhancement.
⚡ Executive Takeaway
On Tuesday night we wrote that Amylyx was the textbook candidate for column three of the ledger, winners selling equity into the pop, and we said watch the wire. The wire took less than a day: a $350 million offering, announced before the market could even finish repricing the stock. That is the second time this month the pattern has run on schedule, after Silence sold $201.3 million within days of divesiran, and it is worth being precise about what the ledger is actually for. It does not predict trial outcomes. It predicts what companies do in the first 48 hours after an outcome, because balance sheet behavior after a binary is far more regular than the binaries themselves.
The exception defines the rule. The week's biggest binary resolved on Wednesday, and its owners will never appear in the ledger: Merck and Moderna took a Phase 3 melanoma win, sold nothing, raised nothing, wrote nothing contingent, and did not even tell you the number. Holding your own binaries in silence is what scale buys. Everyone else trades theirs within a day, and you can set your watch by it. 👉 Read Full Analysis
🧬 Oncology & Vaccines
The individualized mRNA cancer therapy cleared its first Phase 3. The size of the win stays secret until a medical congress. MRK | MRNA
INTerpath-001, the Phase 3 trial of intismeran autogene plus pembrolizumab in 1,137 patients with completely resected stage IIB to IV melanoma, met both its primary recurrence free survival endpoint and its key secondary distant metastasis free survival endpoint at a prespecified interim analysis, with no new safety signals. The companies called the improvements statistically significant and clinically meaningful and disclosed nothing else; data go to an upcoming international medical meeting, and they will engage regulators on filings. The context is the five year Phase 2b, where the combination cut recurrence or death risk 49 percent in 157 patients, and the caution is that the Phase 3 reaches into lower risk stage IIB disease where effects are harder to show. Fierce Biotech reports Citi framed a hazard ratio of 0.72 or better as positive and 0.65 or better as a clear win, and that the FDA turned down an accelerated approval bid on the Phase 2b data in 2024. Nine more trials across lung, bladder, renal, pancreatic, and gastric cancers ride on this readout. The Pro brief covers what a topline with no numbers is worth and why the filing question is as much about the factory as the biology.
💰 Capital Markets
Amylyx went to the wire we told you to watch: $350 million, one day after the readout. AMLX
Amylyx announced a proposed underwritten public offering of $350.0 million of common stock on Tuesday evening, with a 30 day underwriters option for up to $52.5 million more, one day after avexitide cut hypoglycemic events 55 percent in the Phase 3 LUCIDITY trial. Proceeds go to pre commercial activities for avexitide, including manufacturing capacity, plus R&D and working capital; Leerink, Morgan Stanley, Guggenheim, and LifeSci Capital run the books, and the deal comes off a shelf that went effective in March. As of Wednesday night it had not priced. The logic is straightforward: an NDA is due by year end under Breakthrough Therapy designation, a launch has to be built in a population where the diagnosis barely exists yet, and the cheapest equity a small company will ever sell is the equity it sells the day after a clean pivotal win. Silence ran the identical play two weeks ago at $201.3 million. This entry goes straight into column three of the ledger, and the open question worth watching is the pricing: how much discount the market demands from a company whose regulatory risk is largely behind it.
🏛️ FDA Leadership
The Overton nomination is official now. Everything we wrote Tuesday night still holds.
President Trump formally announced on Wednesday, via a post on Truth Social, that he is nominating Dr. Heidi Overton to run the FDA, converting Tuesday's sourced reports into an official nomination. She requires Senate confirmation and no hearing date has been set. Nothing else changed. Overton's record remains pricing deals, the vaccine schedule, and the food pyramid, with nothing on the two questions that have defined this agency for sponsors this summer, post hoc analyses and manufacturing findings. Every decision on the calendar through the fourth quarter, Capricor, Scholar Rock, rusfertide, Summit, Vertex, is still made by the acting structure. Yesterday's edition carried the full analysis of what a nominee can and cannot change; the one addition tonight is that the confirmation clock has actually started, and the hearing date, when it comes, is the first date on which the next FDA's philosophy could go on the record.
⚖️ Policy
Teva lost the big IRA questions and won a small one that will outlive this case. TEVA
The D.C. Circuit ruled against Teva on both of its central challenges to Medicare drug price negotiation on Tuesday, holding that CMS may treat Austedo and Austedo XR as a single negotiation eligible drug because they share an active moiety and a manufacturer, and that the program violates no due process rights because Medicare participation is voluntary. But the panel revived Teva's challenge to CMS's bona fide marketing standard, the rule that decides when generic competition actually exists for negotiation purposes, and sent it back to the district court for a merits ruling. The unanimous opinion drew a line that matters beyond Teva: the statute's bar on judicial review covers CMS's drug specific determinations, not the generally applicable legal standards behind them. That is now the roadmap for every manufacturer hunting for a reviewable question inside the IRA, and it lands as the negotiation program moves into its second cycle with the industry's core constitutional arguments now rejected by every appellate court to reach them.
📋 Quick Hits
Tolerance Bio licensed efineptakin alfa (NT-I7), NeoImmuneTech's long acting interleukin 7 fusion protein, for the Americas and Europe: equity of undisclosed size plus up to $260 million in development and sales milestones plus tiered royalties, with essentially no cash upfront. The asset has been dosed in more than 800 subjects; Tolerance plans Phase 2 in thymic function enhancement, starting in HIV immunological non response. Column six of the ledger, at the zero cash end of the curve.
Merck and Sarah Cannon Research Institute announced a collaboration to expand access to oncology clinical trials, per the companies' August 13 release, covered by Fierce Biotech on Wednesday; no financial terms were disclosed. MRK
STAT reports that gene editing experts are dissecting HuidaGene's disclosure decisions in the wake of the boy's death in its Duchenne trial in China; the detailed reporting is behind STAT's paywall. The China trial transparency thread continues.
Capricor issued no new release and the FDA has published no new goal date for deramiocel; the August 22 date, this Saturday, formally stands. CAPR
📖 In Today's Full Analysis
Be sure to read the full article for all the details, including:
The full INTerpath-001 design table and the Phase 2b versus Phase 3 comparison, including the hazard ratio bars analysts set before the readout
The Amylyx offering term sheet: size, option, bookrunners, use of proceeds, and the Silence precedent
The Teva ruling claim by claim: what was rejected, what was revived, and the reviewability line the court drew
The Tolerance Bio deal terms and the updated seven column binary ledger heading into Friday's tally
🔒 BioMed Nexus Pro
In Today's Pro Brief...
🧠 The number Merck and Moderna did not tell you: what a topline with no effect size is worth, the hazard ratio bars that separate a Keytruda upgrade from a new paradigm, and why the filing runs through the factory as much as the biology
💊 The 24 hour rule: what Amylyx's instant raise confirms about post readout behavior, the one detail in the pricing that tells you how the market grades a de risked binary, and the anomaly worth hunting for
📊 A license with no cash in it: how Tolerance Bio's zero cash structure extends this week's pricing curve, and why the Teva remand adds a courtroom column entry nobody is modeling
🎯 Plus the catalysts to watch into Friday's full calendar and ledger tally
A Phase 3 win with no number attached, a raise that arrived exactly on schedule, and a court that closed the big doors while quietly leaving a small one open. Friday we tally the whole ledger. What are you watching? Reply to this email.
Sponsorship slots for 2026 are limited. See packages and pricing →
NEW: BioMed Nexus Signals, weekly sales intelligence for life sciences BD teams. Learn more →